CatalYm
PrivateLast Round
Series D
Jul 16, 2024
Total Funding Raised
$260.4M
Momentum Score
25 /100
Company Overview
Catalym is a biopharmaceutical company focused on developing antibodies that enhance the tumor micro-environment, thereby empowering cancer patients' immune systems to improve treatment options and overall quality of life.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CatalYm Comps
Public and private peers based on sector, stage, and business model.
CatalYm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Jul 16, 2024 | ||||
| Series C | Nov 22, 2022 | ||||
| Series B | Nov 10, 2020 |
Key People
Founding team and executive leadership
CatalYm Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A, Series D, Series C |
| Omega Funds | Series D |
| Vesalius Biocapital III | Series D, Series C, Series B |
| Gilde Healthcare | Series D |
| Novartis Venture Fund | Series D, Series C, Series B |
| Vesalius Biocapital Partners | Series D |
| Wachstumsfonds Bayern | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Lead antibody visugromab advances to Phase 2b studies for solid tumors.
- Apr 25, 2025
New data on GDF-15 blockade technology to be presented at AACR 2025.
CatalYm Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about CatalYm's valuation, stock price, and market status.
